APOE and Cognitive impairment: It is assumed that a higher dosage of DHA is required to ensure adequate bioavailability in the brain, and that the APOE4 genotype is associated with a reduced delivery of DHA and eicosapentaenoic acid (EPA) to the brain prior to the onset of cognitive impairment.